Trial Profile
Dose-ascending, Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ACP-001 (TransCon PEG hGH)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Lonapegsomatropin (Primary) ; Growth hormones
- Indications Somatotropin deficiency
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms TransCon PEG hGH
- Sponsors Ascendis Pharma
- 19 Mar 2018 According to Ascendis Pharma media release, interim data from this trial will be presented at ENDO 2018
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society
- 04 Apr 2016 Results assessing optimal release profile of unmodified hGH from the prodrug and to predict the relationship between TransCon Growth Hormone dose and serum concentrations of released unmodified hGH presented at The 98th Annual Meeting of the Endocrine Society.